Background Recent guidelines caution against the use of non-vitamin K antagonists oral
anticoagulants (NOACs) in patients with extremely high body weight (≥ 120 kg) due to lack …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Introduction: Apixaban dosing in atrial fibrillation (AF) is 5 mg BID or 2.5 mg BID in patients
with≥ 2 dose-reduction criteria: age> 80 years, weight< 60 kg, or creatinine> 1.5 mg/dl …

Atrial fibrillation (AF) is associated with increased risk of stroke and mortality. Prevention of
thromboembolism is the foundation of managing this common disease. 1 The nonvitamin K …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Background: Clinical trials comparing direct oral anticoagulants (DOACs) to warfarin
included only a small number of patients that weighed less than 60 kilograms (kg). The …

Background: Body Mass Index (BMI) is a risk factor for atrial fibrillation (AF). Few studies
have examined the relations between BMI and outcomes in patients with AF treated with …

Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …